September 10, 2025

Impact of a new diagnostic pathway for prostate cancer - From systematic transrectal to targeted MRI fusion transperineal biopsies

View Full Paper

Ask AI

Bookmark

The new diagnostic pathway significantly increased prostate cancer detection rates, notably by over 24%.
The 2023 cohort reported a median Gleason score of 7, indicating more clinically significant cancers detected compared to 6 in 2018.
Transitioning to targeted transperineal biopsies reduced hospital admissions from 11.3% to 3%, a significant improvement.
Despite increased detection rates, treatment plans and risk group classifications remained consistent with previous evaluations.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis shows increased prostate cancer detection rates with targeted MRI fusion biopsies, suggesting improvements in clinical outcomes.

Cite This Study

Kristensen et al. (2025) studied this question.

synapsesocial.com/papers/68c23abeb210217d64782639 https://doi.org/10.21203/rs.3.rs-7371006/v1

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows increased prostate cancer detection rates with targeted MRI fusion biopsies, suggesting improvements in clinical outcomes.

Impact of a new diagnostic pathway for prostate cancer - From systematic transrectal to targeted MRI fusion transperineal biopsies

Key Points

Discussion

Implication

Cite This Study

Impact of a new diagnostic pathway for prostate cancer - From systematic transrectal to targeted MRI fusion transperineal biopsies

Key Points

Discussion

Implication

Cite This Study